News in brief

April 2007
Nature Medicine;Apr2007, Vol. 13 Issue 4, p394
Academic Journal
The article presents news developments related to nature medicine in the United States. These include: pharmaceutical company Merck has stopped lobbying state governments to mandate vaccines for cervical cancer, more than one in four women under 60 is infected with at least one strain of the human papilloma virus, second-generation schizophrenia drugs are not significantly better than the first and they must be supplemented with vocational training and family counseling.


Related Articles

  • Bye bye pap tests?  // Herizons;Fall98, Vol. 12 Issue 3, p11 

    Reports that drugs company Merck and Co. is developing a vaccine to prevent cervical cancer. Human papilloma virus (HPV) as cause of the cancer.

  • Cervical cancer vaccine.  // Cortlandt Forum;Sep2006, Vol. 19 Issue 9, p12 

    The article offers information about Gardasil, a cervical cancer vaccine manufactured by Merck & Co. Inc. The Gardasil is made of protein of quadrivalent human papillomavirus (HPV) types 6, 11, 16, and 18, which are produced in recombinant. A study assesses the effectiveness of Gardasil in...

  • Cervical cancer on its way out. Houlton, Sarah // European Pharmaceutical Executive;Sep2006, p12 

    The article reports that cervical cancer can be cured through vaccines Gardasil from Merck & Co. Inc. and Cervarix from GlaxoSmithKline. Cervical cancer is considered as the second most common form of women diseases and the biggest cancer killer caused by human papilloma virus. Both vaccines...

  • New CDC recommendations for HPV vaccine.  // Contemporary OB/GYN;Aug2006, Vol. 51 Issue 8, p21 

    The article focuses on the approval by the U.S. Food and Drug Administration of Gardasil, the first vaccine developed to protect women against cervical cancer. The vaccine, which was developed by Merck & Co., is highly effective against four types of human papillomavirus, two of which can cause...

  • Quadrivalent Human Papillomavirus (HPV) Vaccine. Deresinski, Stan // Clinical Infectious Diseases;9/15/2007, Vol. 45 Issue 6, pv 

    The article offers information on the quadrivalent human papillomavirus vaccine (HPV) gardasil, manufactured by Merck & Co. Inc. Gardasil contains virion-like particles expressing key surface antigens of HPV-16 and HPV-18, the 2 oncogenic human papillomaviruses found in association with cervical...

  • Gardasil Again Denied Approval for Women 27-45.  // Clinical Infectious Diseases;3/1/2009, Vol. 48 Issue 5, piv 

    The article reports on the approval for the use of Merck & Co. Inc.'s Gardasil cervical cancer vaccine by women aged 27-45. It is stated that Gardasil's efficacy drops once females have been exposed to human papilloma virus (HPV). However, analyst Tim Anderson mentions that Merck could have...

  • Vaccines against cervical cancer provoke US controversy. Tanne, Janice Hopkins // BMJ: British Medical Journal (International Edition);4/8/2006, Vol. 332 Issue 7545, p814 

    The article focuses on a new vaccine for cervical cancer which is inciting controversy in the United States from conservative groups concerned that it should not be given to 11 and 12-year-old children, as it may encourage sexual activity. The function of the vaccine, which targets the sexually...

  • HPV vaccine could save millions of lives. Mitrzyk, Beatriz Manzor // Pharmacy Today;Aug2006, Vol. 12 Issue 8, p11 

    The article offers information on the human papillomavirus vaccine (Gardasil) manufactured by Merch & Co. Inc. Gardasil has been found to prevent cervical cancer and genital warts. The U.S. Food and Drug Administration licensed the vaccine for girls and women from between 9 to 26 years old....

  • New biologics.  // Formulary;Jul2006, Vol. 41 Issue 7, p306 

    The article provides information on Gardasil, an approved quadrivalent human papillomavirus recombinant vaccine for the prevention of cervical cancer from Merck. Gardasil is prepared from the virus-like particles of the major capsid protein of the human papillomavirus. Safety, efficacy, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics